Company news

Adhera Therapeutics Inc. news in 2017

Adhera Therapeutics Inc.'s news releases, calls and decks from 2017, newest first.

View company

Marina Biotech Appoints Isaac Blech to its Board of Directors

November 27, 2017

Marina Biotech Appoints Chief Legal Officer to Support Legal, Transactional and Intellectual Property Portfolio Initiatives

October 19, 2017

Marina Biotech Appoints Amit Shah as Chief Financial Officer

October 5, 2017

Windlas Healthcare Invests $2 Million in Working Capital to Support Marina Biotech’s Manufacturing Initiatives

August 21, 2017

Marina Biotech Announces 1-for-10 Reverse Stock Split in Preparation for Proposed Up-Listing of its Common Stock to the NASDAQ Capital Market

August 2, 2017

Marina Biotech Announces Binding Letter of Intent for the Sale of its DiLA2 Delivery Platform

July 25, 2017

Marina Biotech Acquires DyrctAxess™ Technology Platform to Support Sales and Marketing of Prestalia®

July 24, 2017

Marina Biotech Announces a License Agreement to SMARTICLES and CRN platforms for Antisense DNA therapeutics

July 19, 2017

Marina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive Chairman

July 5, 2017

Marina Biotech Appoints Chief Commercial Officer to Lead Sales and Marketing of Prestalia(R)

June 26, 2017

Marina Biotech Acquires Prestalia(R), a U.S. FDA Approved Drug for Patients Whose Blood Pressure Is Not Adequately Controlled by Monotherapy

June 6, 2017

Marina Biotech to Introduce Its Therapeutic Microbiome Programs Against Gastrointestinal Diseases

May 30, 2017

Marina Biotech to Participate in Joseph Gunnar's Pioneers 2017 Conference on May 2

April 27, 2017

Marina Biotech Signs Definitive Agreement with Windlas Healthcare to Manufacture IT-102 FDC Bi-Layer Tablet

April 6, 2017

Marina Biotech Provides Business Update

April 6, 2017

Marina Biotech to Present Data on IT-102 and IT-103 at 2017 American Association for Cancer Research Annual Meeting

March 29, 2017

Marina Biotech to Present Data on Vascular Resistance and Cancer at the Endocrine Society Annual Meeting on April 1

March 24, 2017

Marina Biotech to Present A Late Breaking Poster on the Safety and Tolerability of CEQ508 for FAP at the Society of Toxicology 56th Annual Meeting on March 16

March 13, 2017

Marina Biotech to Present New Data for IT-102 and IT-103 at the 7th International Conference on Fixed Combination in Cannes, France

March 2, 2017

Marina Biotech to Participate in the 29th Annual ROTH Conference

March 1, 2017

Marina Biotech Engages KCSA Strategic Communications as Investor Relations Counsel

February 28, 2017

Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer

February 21, 2017

Marina Biotech Announces Key Additions to its Executive Management Team

February 14, 2017

Marina Biotech Completes Share Issuance at a Valuation of $0.29 Per Share

February 10, 2017

Marina Biotech Announces a License Agreement to SMARTICLES

February 7, 2017

Marina Biotech Granted European Claims Covering Bacteria Mediated Gene Silencing

January 3, 2017

Decks in 2017